- Short Courses
- Exhibits & Sponsorship
- Conference Presentations
- ISPOR Latin America Summit 2019
ISPOR Latin America 2019
- Exhibits & Sponsorship
ISPOR Europe 2019
- Abstract Submission
- Short Courses
- Exhibits & Sponsorship
ISPOR Summit 2019
- ISPOR 2019
- ISPOR Warsaw 2019
- ISPOR Europe 2018
- ISPOR Summit 2018
- ISPOR Dubai 2018
- ISPOR Asia Pacific 2018
- ISPOR 2018
- ISPOR Europe 2017
- ISPOR Latin America 2017
- ISPOR Asia Pacific 2016
- Submit Abstract
- Exhibits & Sponsorships
- Awards & Grants
- Upcoming Conferences
Education & Training
- In-Person Training
- Introduction to Outcomes Research
- Introduction to Systematic Reviews & Meta-Analysis
- Systematic Review & Meta-Analysis: Applications
- Introduction to Pharmacoeconomics
- Cost-of-Illness/Cost-Estimation (COI/CE)
- Cost-Minimization/Cost-Consequence (CMA/CCA)
- Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA)
- Modeling Health Care Costs – Part I: Characteristics of Health Care Costs
- Modeling Health Care Costs – Part II: Methods and Guidelines for Estimating Health Care Costs
- Modeling Health Care Costs – Part III: Estimation from Censored Data
- Introduction to Budget Impact Analysis (BIA) - Part I
- Introduction to Budget Impact Analysis (BIA) - Part II
- Markov Model Toolkit: Concepts, Assumptions and Examples
- An Introduction to Choice-Based Conjoint Analysis (Discrete Choice Experiments)
- Health-Related Quality of Life (HRQOL) – Basics
- Patient Reported Outcomes: Analysis and Interpretation
- Patient Reported Outcomes: Instrument Development
- Item Response Theory: A Conceptual Introduction
- Preparing for Multinational Clinical Trials: Translation and Cultural Adaptations of PRO Measures
- Evidence Generation for Patient Reported Outcome (PRO) Label Claims (FDA Requirements)
- Intermediate Retrospective Observational Study - Propensity Scoring Methods
- Use of Public Survey Data in Health Outcomes Research
- Using RWE to Improve Healthcare Decision-making in Asia Pacific
- Top 10 HEOR Trends of 2019
- The Use of MCDA for HTA Agencies
- MCDA - How to Guide of Different Methods for Assessment of Rare Disease HT
- Virtualizing Long-Term Follow-Up Studies for Gene Therapy Products
- Is the FDA's New Guidance a Watershed Moment for Real-world Evidence?
- Distance Learning
- ISPOR issue panels are designed to stimulate real debate on new or controversial topics in health economics and outcomes research or use of outcomes research in healthcare decision making.
- A successful issue panel will debate an important and/or timely HEOR issue. Each panelist is expected to provide a different perspective on the issue.
- To assure lively discussion, panelists should be from different institutions and/or work environments.
- Example of an issue panel proposal submission is available here.
Issue panel submissions should be organized as follows:
- TITLE: Provide a title that accurately describes the issue and is framed as a question. The title should be in all CAPS.Examples:
- MULTI-INDICATION PRICING: DO WE WANT IT? CAN WE OPERATIONALIZE IT?
- DESIGNING A PATIENT-CENTERED VALUE FRAMEWORK TO GUIDE SHARED DECISION MAKINGIN ONCOLOGY: WHY, WHAT, AND HOW?
- ARE EXISTING HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS INADEQUATE FORESTABLISHING VALUE FOR POTENTIALLY TRANSFORMATIVE GENE THERAPIES?
- MODERATOR/PANELISTS: An issue panel is comprised of 1 moderator and a minimum of 2 and maximum of 3 panelists.
- To assure lively debate, panelists should be from different institutions and/or work environments representing different perspectives on the debate.
- Panelists should present distinct views on the topic.
- Provide the names, degrees, positions, city, state, country and email addresses for the moderator/panelists.
- SUBJECT FOR DEBATE: A successful issue panel will debate an issue and have multiple perspectives represented by the panelists. Provide the question which will be the subject of the debate.
- ISSUE: Provide a clear definition of the issue to be presented and debated.
- OVERVIEW: Provide background information and details on the material to be presented. Include speaker presentation length, e.g., 15 minutes, and state the allotted time to address the audience discussion and debate criterion. It is helpful to include which stakeholders will benefit from attending.
- LENGTH of PROPOSAL (Issue and Overview): 300 words
- PANELIST’S PERSPECTIVE: Provide a description of each panelist’s perspective on the debate topic.
- Example 1: Dr. Glick will discuss challenges in designing a patient-centered value framework, including addressing tensions between the societal and patient perspective. Ms. Sonet will represent patient perspectives, offering insights from patient-centered research conducted by CancerCare. She will highlight factors important to cancer patients and approaches to collecting such information in clinical practice to support a customized patient-centered decision tool. Dr. Phelps will argue that methods such as multi-criteria decision analysis can be used to develop a scoring approach to inform shared decision-making using a customized tool.
- Example 2: Jaime Caro will argue that the development of open-source models is essential for cost-effectiveness analysis to be viewed as a reliable input to decision making and Renée Arnold will argue that the impact on intellectual property rights, model “ownership”, oversite and, consequently, the incentives and resources available to develop and maintain models are prohibitive.
TOPIC CATEGORIES AND SUB-CATEGORIES FOR ISSUE PANEL SUBMISSIONS
Select the topic/subtopic that best describes your proposal from the list below. Click on the topics below to see their respective subtopics.
Clinician Reported Outcomes
Comparative Effectiveness or Efficacy
Clinician Outcomes Assessment
Relating Intermediate to Long-term Outcomes
Cost/Cost of Illness/Resource Use Studies
Budget Impact Analysis
Thresholds & Opportunity Cost
Trial-based economic evaluation
Work & Home Productivity - Indirect Costs
Value of Information
Novel & Social Elements of Value
Safety & Pharmacoepidemiology
Prevalence, Incidence, & Disease Risk Factors
Disease Classification & Coding
Approval & Labeling
Pricing Policy & Schemes
Reimbursement & Access Policy
Insurance Systems & National Health Care
Public Spending & National Health Expenditures
Coverage with Evidence Development & Adaptive Pathways
Health Disparities & Equity
Hospital and Clinical Practices
Pharmacist Interventions and Practices
Quality of Care Measurement
Treatment Patterns and Guidelines
Systems & Structure
Value Frameworks & Dossier Format
Decision & Deliberative Processes
Diagnostics & Imaging
Artificial Intelligence, Machine Learning, Predictive Analytics
Confounding, Selection Bias Correction, Causal Inference
Modeling & Simulation
PRO & Related Methods
Adherence, Persistence, & Compliance
Stated Preference & Patient Satisfaction
Health State Utilities
Patient-reported Outcomes & Quality of Life Outcomes
Patient Behavior and Incentives
Instrument Development, Validation, & Translation
Academic & Educational
Best Research Practices
Geographic & Regional
Data Protection, Integrity, & Quality Assurance
Health & Insurance Records Systems
Distributed Data & Research Networks
Reproducibility & Replicability
Pragmatic Trials & Large Simple Trials
Prospective Observational Studies
Electronic Medical & Health Records
Administrative Claims Data
Surveys & Expert Panels
Decision Modeling & Simulation
Literature Review & Synthesis
Meta-analysis & Indirect Comparisons
CRITERIA FOR EVALUATION OF ISSUE PANELS
Overall, issue panel acceptance is based on the quality of the proposal/debate presented and the topic’s importance for inclusion and discussion in this conference’s scientific program.
All issue panel submissions are judged according to these criteria:
- The information / issue(s) presented are valuable to the health economic & outcomes researcher or the healthcare decision-maker
- Is the issue panel clearly a debate on an issue?
- Is the issue clearly defined?
- Is more than one perspective identified?
- Is the background information (included in the overview) clear and concise?
- Is there time allotted for audience discussion and debate?
- Presenter diversity, i.e., different stakeholders, work environments and/or geographic locations.